Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With

Frexalimab (anti-CD40L) showed strong Phase 2 results in RMS with ~89% reduction in new Gd-enhancing T1 lesions vs placebo at week 12. Mechanism is well-validated and ARR endpoint vs active comparator teriflunomide (a modestly effective DMT) is achievable—multiple higher-efficacy agents (ocrelizumab, ofatumumab) have beaten teriflunomide on ARR. Risks: active comparator raises bar vs placebo, long 156-week readout, and CD40L class has historical safety concerns. Sanofi's commitment and Ph2 signal support positive readout.

Phase 3 completion of enrollment, an adjudicated ARR endpoint, ITT analysis, and an event-driven design support execution and endpoint reliability. However, superiority versus active teriflunomide is demanding, duration varies, and no prior efficacy results are provided, limiting conviction.

Phase 3, active-controlled relapsing-MS program uses adjudicated ARR, a well-established and sensitive efficacy endpoint. Long event-driven follow-up and teriflunomide comparator support detection of benefit, but no prior efficacy data, sample size, or effect-size assumptions are provided; attrition and operational variability remain meaningful risks.

Phase 3, active-not-recruiting execution and Sanofi sponsorship support completion; adjudicated ARR is objective and modeled in ITT with prespecified stratification. However, the active teriflunomide control, event-driven duration, relapse-rate variability, and absence of efficacy magnitude in the fields leave meaningful failure risk.

Phase 3, event-driven vs active comparator teriflunomide; standard adjudicated ARR primary endpoint in ITT with negative binomial model; relapsing MS patients 18-55; proper stratification and min 12mo treatment; no design red flags.

Frexalimab is an anti-CD40L mAb with strong Phase 2 data, showing an 89% reduction in Gd+ T1 lesions vs placebo—a magnitude highly predictive of robust ARR suppression in MS. OLE data showed a sustained low ARR of 0.08 at 96 weeks. With N=1400, this Phase 3 trial is fully powered to demonstrate superiority over the moderate-efficacy comparator teriflunomide (expected ARR ~0.11-0.15).

Phase 2 frexalimab showed 89% reduction in Gd-enhancing lesions vs placebo but limited relapse data. Phase 3 uses ARR vs active comparator teriflunomide, a modest efficacy DMT. Superiority is plausible but not assured given long event-driven design and execution risk. Estimated 55% success.

Frexalimab Phase 2b showed strong MRI lesion reduction in RMS, and the active comparator teriflunomide is a moderate-efficacy DMT that multiple agents have beaten on ARR. Sanofi has strong operational execution. However, anti-CD40L is a novel mechanism for MS with uncertain translation from MRI to clinical relapse endpoints, and historical thromboembolic safety concerns with CD40L antibodies add risk. Net odds favor success but with meaningful residual uncertainty.

Frexalimab targets CD40L, a novel MOA in MS with strong Phase 2 efficacy signals. Sanofi's active-not-recruiting status suggests robust enrollment. Head-to-head vs teriflunomide is a standard comparator; given the strong mechanistic rationale and prior data, a positive ARR result is likely despite Phase 3 execution risks.

Phase 3 trial compares Frexalimab to established teriflunomide on ARR, a hard clinical endpoint. Active not recruiting, with ~1.2 years to primary completion, means limited data on enrollment and event rates. The presence of placebo arms adds uncertainty about incremental benefit. Overall, modest chance of a statistically positive ARR result.

Frexalimab is a CD40L inhibitor with strong Phase 2 data in MS showing 89% reduction in new Gd+ lesions vs placebo. Phase 3 design is event-driven with ~40-month max follow-up, powered for ARR vs teriflunomide (active comparator). Sanofi has deep MS expertise. Active-not-recruiting status suggests enrollment complete, reducing execution risk. Primary endpoint is standard and well-defined. Main risks: longer duration increases dropout/noise, and anti-CD40L class has seen thrombotic safety signals historically (though not in Phase 2).

Frexalimab Phase 2 showed 89-96% reduction in Gd+ lesions vs placebo, strong signal. However, Phase 3 uses active comparator teriflunomide (ARR ~0.35 baseline), making superiority harder than vs placebo. Novel CD40L mechanism is differentiated. Enrollment complete (Active Not Recruiting) is positive operational signal. Event-driven design with 12-month minimum treatment. Active comparator risk partially offsets strong prior data, leaving moderate confidence.